GLP-1 ↔ GLP-1+GIP генетическая интерпретация терапии ожирения

Справочные данные

Глобальный реестр препаратов GLP-1/GIP

Справочная таблица агонистов GLP-1 и двойных агонистов GIP/GLP-1, зарегистрированных или представленных на международных рынках.

Обновлено: 2026-08-01.

Записей: 142
GLP1 or GLP1+GIP
INN / mechanism
Brand name
Country / market / regulator
Route and frequency of administration
Manufacturer / marketing authorization holder
Year of launch / registration
Dosages in the prescribing information
GLP1SemaglutideOzempicUnited States and multiple markets; FDA/national regulatorsSubcutaneous injection once weeklyNovo Nordisk20170.25; 0.5; 1; 2 mg per administration (available presentations vary by country)
GLP1SemaglutideOzempic TabletsUnited States; FDAOrally once dailyNovo Nordisk20261.5; 4; 9 mg
GLP1SemaglutideRybelsusUnited States, EU, and other marketsOrally once dailyNovo Nordisk20193; 7; 14 mg; in some markets, new formulation: 1.5; 4; 9 mg
GLP1SemaglutideWegovyUnited States, EU, United Kingdom, Canada, Brazil, India, and other marketsSubcutaneous injection once weeklyNovo Nordisk20210.25; 0.5; 1; 1.7; 2.4 mg; in the United States/Brazil, up to 7.2 mg/week for certain adults
GLP1SemaglutideWegovy TabletsUnited States; subsequent approvals by individual regulatorsOrally once dailyNovo Nordisk2025/20261.5; 4; 9; 25 mg
GLP1SemaglutideKayshildEuropean Union; EMA/European CommissionSubcutaneous injection once weeklyNovo Nordisk20260.25; 0.5; 1; 1.7; 2.4 mg
GLP1SemaglutidePlosbrioCanada; Health CanadaSubcutaneous injection once weeklyNovo Nordisk Canada20250.25; 0.5; 1; 2 mg
GLP1SemaglutidePoviztraCanada and IndiaSubcutaneous injection once weeklyNovo Nordisk / local commercial partners20250.25; 0.5; 1; 1.7; 2.4 mg
GLP1SemaglutideExtensiorIndia; also South AfricaSubcutaneous injection once weeklyNovo Nordisk; in India, in partnership with Abbott20260.25; 0.5; 1 mg
GLP1SemaglutideSemaglutide InjectionCanada; Health CanadaSubcutaneous injection once weeklyDr. Reddy’s Laboratories20260.25; 0.5; 1 mg
GLP1SemaglutideAPO-Semaglutide InjectionCanada; Health CanadaSubcutaneous injection once weeklyApotex20260.25; 0.5; 1 mg
GLP1SemaglutideSevmiaCanada; Health CanadaSubcutaneous injection once weeklyApotex20260.25; 0.5; 1; 1.7; 2.4 mg
GLP1SemaglutideAspen-SemaglutideCanada; Health CanadaSubcutaneous injection once weeklyAspen Pharmacare Canada20260.25; 0.5; 1 mg
GLP1SemaglutideTasylevSaudi Arabia; SFDASubcutaneous injection once weeklyListed in the SFDA register; local MAH20260.25; 0.5; 1 mg
GLP1SemaglutideOzivyBrazil; AnvisaSubcutaneous injection once weeklyEMS S/A20260.25; 0.5; 1 mg
GLP1SemaglutideOwozyBrazil; AnvisaSubcutaneous injection once weeklyÁvita Care Importação e Distribuição de Produtos Ltda.20260.25; 0.5; 1 mg (T2D presentations; exact package configurations per national prescribing information)
GLP1SemaglutideSeemasunBrazil; AnvisaSubcutaneous injection once weeklySun Farmacêutica do Brasil Ltda.20260.25; 0.5; 1 mg (T2D presentations; exact package configurations per national prescribing information)
GLP1SemaglutideZempneoBrazil; AnvisaSubcutaneous injection once weeklyBrainfarma Indústria Química e Farmacêutica S.A.20260.25; 0.5; 1 mg (T2D presentations; exact package configurations per national prescribing information)
GLP1SemaglutideSemavyBrazil; AnvisaSubcutaneous injection once weeklyCosmed Indústria de Cosméticos e Medicamentos S.A.20260.25; 0.5; 1 mg (T2D presentations; exact package configurations per national prescribing information)
GLP1SemaglutideOrsemaBrazil; AnvisaSubcutaneous injection once weeklyRanbaxy Farmacêutica Ltda. / Sun Pharma20260.25; 0.5; 1 mg (T2D presentations; exact package configurations per national prescribing information)
GLP1SemaglutideExtensiorSouth Africa; SAHPRASubcutaneous injection once weeklyNovo Nordisk / Acino20260.25; 0.5; 1 mg
GLP1SemaglutideSemaglutide Injection (brand name not disclosed)South Africa; SAHPRASubcutaneous injection once weeklySun Pharmaceutical Industries20260.25; 0.5; 1 mg
GLP1SemaglutideNoveltreatIndia; DCGI/CDSCOSubcutaneous injection once weekly; oral presentations once dailySun Pharmaceutical Industries20260.25; 0.5; 1; 1.7; 2.4 mg
GLP1SemaglutideSematrinityIndia; DCGI/CDSCOSubcutaneous injection once weekly; oral presentations once dailySun Pharmaceutical Industries2026Two registered presentations for T2D; delivered doses of 0.25/0.5 and 1 mg
GLP1SemaglutideObedaIndia; DCGI/CDSCOSubcutaneous injection once weekly; oral presentations once dailyDr. Reddy’s Laboratories2026Pens containing 2 mg and 4 mg in total; doses of 0.25; 0.5; 1 mg/week
GLP1SemaglutideSemaglynIndia; DCGI/CDSCOSubcutaneous injection once weekly; oral presentations once dailyZydus Lifesciences / Zydus Healthcare20260.25; 0.5; 1; 1.7; 2.4 mg
GLP1SemaglutideMashemaIndia; DCGI/CDSCOSubcutaneous injection once weekly; oral presentations once dailyZydus Lifesciences20260.25; 0.5; 1; 1.7; 2.4 mg
GLP1SemaglutideAltermeIndia; DCGI/CDSCOSubcutaneous injection once weekly; oral presentations once dailyZydus Healthcare20260.25; 0.5; 1; 1.7; 2.4 mg
GLP1SemaglutideSemanextIndia; DCGI/CDSCOSubcutaneous injection once weekly; oral presentations once dailyLupin; manufactured by Zydus20260.25; 0.5; 1; 1.7; 2.4 mg
GLP1SemaglutideLivariseIndia; DCGI/CDSCOSubcutaneous injection once weekly; oral presentations once dailyLupin; manufactured by Zydus20260.25; 0.5; 1; 1.7; 2.4 mg
GLP1SemaglutideSembolicIndia; DCGI/CDSCOSubcutaneous injection once weekly; oral presentations once dailyTorrent Pharmaceuticals2026Injection: 0.25; 0.5; 1 mg; separate oral presentations: 3; 7; 14 mg
GLP1SemaglutideSemalixIndia; DCGI/CDSCOSubcutaneous injection once weekly; oral presentations once dailyTorrent Pharmaceuticals2026Injection: 0.25; 0.5; 1 mg; separate oral presentations: 3; 7; 14 mg
GLP1SemaglutideGlipiqIndia; DCGI/CDSCOSubcutaneous injection once weekly; oral presentations once dailyGlenmark Pharmaceuticals20260.25; 0.5; 1 mg
GLP1SemaglutideSemasizeIndia; DCGI/CDSCOSubcutaneous injection once weekly; oral presentations once dailyAlkem Laboratories20260.25; 0.5; 1 mg
GLP1SemaglutideObesemaIndia; DCGI/CDSCOSubcutaneous injection once weekly; oral presentations once dailyAlkem Laboratories20260.25; 0.5; 1; 1.7; 2.4 mg
GLP1SemaglutideHepaglideIndia; DCGI/CDSCOSubcutaneous injection once weekly; oral presentations once dailyAlkem Laboratories20260.25; 0.5; 1 mg; 1.7/2.4 mg may be available for specific indications
GLP1SemaglutideSundaeIndia; DCGI/CDSCOSubcutaneous injection once weekly; oral presentations once dailyEris Lifesciences20260.25; 0.5; 1 mg
GLP1SemaglutideSemanatIndia; DCGI/CDSCOSubcutaneous injection once weekly; oral presentations once dailyNatco Pharma20260.25; 0.5; 1 mg
GLP1SemaglutideSemafullIndia; DCGI/CDSCOSubcutaneous injection once weekly; oral presentations once dailyNatco Pharma20260.25; 0.5; 1; 1.7; 2.4 mg
GLP1SemaglutideUsemaIndia; DCGI/CDSCOSubcutaneous injection once weekly; oral presentations once dailyUSV Private Limited20260.25; 0.5; 1 mg
GLP1SemaglutideSemabestIndia; DCGI/CDSCOSubcutaneous injection once weekly; oral presentations once dailyMSN Laboratories20260.25; 0.5; 1 mg
GLP1SemaglutideSamakindIndia; DCGI/CDSCOSubcutaneous injection once weekly; oral presentations once dailyMankind Pharma20260.25; 0.5; 1 mg
GLP1SemaglutideSemaneoIndia; DCGI/CDSCOSubcutaneous injection once weekly; oral presentations once dailyIntas Pharmaceuticals20260.25; 0.5; 1 mg
GLP1SemaglutideSemawinIndia; DCGI/CDSCOSubcutaneous injection once weekly; oral presentations once dailyIntas Pharmaceuticals20260.25; 0.5; 1; 1.7; 2.4 mg
GLP1SemaglutideFitaroBangladesh; legally marketed nationallySubcutaneous injection once weeklyIncepta Pharmaceuticals Ltd.≤2026; exact date of first launch not publicly established0.25; 0.5; 1; 1.7; 2.4 mg
GLP1SemaglutideMylendaBangladesh; legally marketed nationallySubcutaneous injection once weeklyBeximco Pharmaceuticals Ltd.≤2026; exact date of first launch not publicly established0.25; 0.5; 1 mg
GLP1SemaglutideMysemaBangladesh; legally marketed nationallySubcutaneous injection once weeklyDrug International Ltd.≤2026; exact date of first launch not publicly established0.25; 0.5 mg
GLP1SemaglutideOrsemaBangladesh; legally marketed nationallySubcutaneous injection once weeklyIncepta Pharmaceuticals Ltd.≤2026; exact date of first launch not publicly established0.25; 0.5 mg
GLP1SemaglutidePotenzaBangladesh; legally marketed nationallySubcutaneous injection once weeklyACI Limited≤2026; exact date of first launch not publicly established0.25; 0.5; 1 mg
GLP1SemaglutidePotenza OBBangladesh; legally marketed nationallySubcutaneous injection once weeklyACI Limited≤2026; exact date of first launch not publicly established0.25; 0.5; 1; 1.7; 2.4 mg
GLP1SemaglutideReglutideBangladesh; legally marketed nationallySubcutaneous injection once weeklyBeximco Pharmaceuticals Ltd.≤2026; exact date of first launch not publicly established0.25; 0.5; 1 mg
GLP1SemaglutideSemagloBangladesh; legally marketed nationallyOnce-weekly injection and/or once-daily tabletsZiska Pharmaceuticals Ltd.≤2026; exact date of first launch not publicly establishedInjection: 0.25; 0.5 mg; tablets: 3; 7 mg
GLP1SemaglutideSemaglo OBBangladesh; legally marketed nationallySubcutaneous injection once weeklyZiska Pharmaceuticals Ltd.≤2026; exact date of first launch not publicly established0.25; 0.5; 1; 1.7; 2.4 mg
GLP1SemaglutideSemaglutBangladesh; legally marketed nationallyOrally once dailyNIPRO JMI Pharma Ltd.≤2026; exact date of first launch not publicly establishedTablets: 3; 7 mg
GLP1SemaglutideSemaslimBangladesh; legally marketed nationallySubcutaneous injection once weeklyBeacon Pharmaceuticals PLC≤2026; exact date of first launch not publicly established0.25; 0.5; 1; 1.7; 2.4 mg
GLP1SemaglutideSematidBangladesh; legally marketed nationallyOrally once dailyACME Laboratories Ltd.≤2026; exact date of first launch not publicly establishedTablets: 3; 7 mg
GLP1SemaglutideSemaxenBangladesh; legally marketed nationallyOrally once dailyEverest Pharmaceuticals Ltd.≤2026; exact date of first launch not publicly establishedTablets: 3; 7 mg
GLP1SemaglutideSemazicBangladesh; legally marketed nationallySubcutaneous injection once weeklySquare Pharmaceuticals PLC≤2026; exact date of first launch not publicly established0.25; 0.5 mg
GLP1SemaglutideAmeglutarRussian Federation; active marketing authorizationSubcutaneous injection once weeklyAMEDART20250.25; 0.5; 1 mg
GLP1SemaglutideVelgiaRussian Federation; active marketing authorizationSubcutaneous injection once weeklyPROMOMED RUS / Biokhimik / Medsintez20240.25; 0.5; 1; 1.7; 2.4 mg
GLP1SemaglutideVelgia EcoRussian Federation; active marketing authorizationSubcutaneous injection once weeklyPROMOMED RUS / Biokhimik20250.25; 0.5; 1; 1.7; 2.4 mg
GLP1SemaglutideDeglyunormRussian Federation; active marketing authorizationSubcutaneous injection once weeklyPharmstandard-UfaVITA20250.25; 0.5; 1 mg
GLP1SemaglutideInsudiveRussian Federation; active marketing authorizationSubcutaneous injection once weeklyPSK Pharma20250.25; 0.5; 1 mg
GLP1SemaglutideInsudive SlimRussian Federation; active marketing authorizationSubcutaneous injection once weeklyPSK Pharma20250.25; 0.5; 1; 1.7; 2.4 mg
GLP1SemaglutideQueensentaRussian Federation; active marketing authorizationSubcutaneous injection once weeklyPROMOMED RUS / Biokhimik / Medsintez20230.25; 0.5; 1 mg
GLP1SemaglutideRebodiya SlimRussian Federation; active marketing authorizationSubcutaneous injection once weeklyPharmstandard-UfaVITA20260.25; 0.5; 1; 1.7; 2.4 mg
GLP1SemaglutideSegluriyaRussian Federation; active marketing authorizationSubcutaneous injection once weeklyR-Pharm / Huadong Pharmaceutical20230.25; 0.5; 1 mg
GLP1SemaglutideSegluriya SlimRussian Federation; active marketing authorizationSubcutaneous injection once weeklyR-Pharm / Huadong Pharmaceutical20260.25; 0.5; 1; 1.7; 2.4 mg
GLP1SemaglutideSelmijiRussian Federation; active marketing authorizationSubcutaneous injection once weeklyKRKA-RUS / Nanjing Kingfriend20250.25; 0.5; 1 mg
GLP1SemaglutideSemavicRussian Federation; active marketing authorizationSubcutaneous injection once weeklyGEROPHARM20230.25; 0.5; 1 mg
GLP1SemaglutideSemavic NextRussian Federation; active marketing authorizationSubcutaneous injection once weeklyGEROPHARM20240.25; 0.5; 1; 1.7; 2.4 mg
GLP1SemaglutideSemaglutideRussian Federation; active marketing authorizationSubcutaneous injection once weeklyMBA-GROUP / AMEDART20260.25; 0.5; 1 mg
GLP1SemaglutideSemaglutide MedsintezRussian Federation; active marketing authorizationSubcutaneous injection once weeklyMedsintez Plant20260.25; 0.5; 1 mg
GLP1SemaglutideSemaltaraRussian Federation; active marketing authorizationOrally once dailyPROMOMED RUS / Biokhimik2025Tablets: 3; 7; 14 mg
GLP1SemaglutideSemvelicaRussian Federation; active marketing authorizationSubcutaneous injection once weeklyAkselgen / Nanopharma Development / Izvarino Pharma20250.25; 0.5; 1 mg
GLP1SemaglutideSemuglinRussian Federation; active marketing authorizationSubcutaneous injection once weeklyPharmasyntez-Nord20250.25; 0.5; 1 mg
GLP1SemaglutideVeloritaIran; IFDA/legally marketedSubcutaneous injection once weeklyCobel Darou20260.25; 0.5; 1 mg; individual presentations may vary
GLP1SemaglutideDutideArgentina; ANMATOrally once dailyLaboratorio Elea20243; 7; 14 mg
GLP1SemaglutideDutide InyectableArgentina; ANMATSubcutaneous injection once weeklyLaboratorio Elea20250.25; 0.5; 1 mg
GLP1SemaglutideObetideArgentina; ANMATSubcutaneous injection once weeklyLaboratorio Elea20250.25; 0.5; 1; 1.7; 2.4 mg
GLP1SemaglutideSEMAAPLaos; Food and Drug DepartmentOrally once dailyAsia Pharmaceutical Industry Sole Co., Ltd.2024Tablets: 3; 7; 14 mg
GLP1SemaglutideL’OSEMLaos; Food and Drug DepartmentOrally once dailyLaos Alliance Pharmaceutical Group2024Tablets: 3; 7; 14 mg
GLP1SemaglutideSEMAGLUMAKSLaos; Food and Drug DepartmentOrally once dailyPharmaceutical Factory No. 22024Tablets: 7; 14 mg
GLP1SemaglutideLUCISEMAGLaos; Food and Drug DepartmentOrally once dailyLucius Pharmaceutical2024Tablets: 7; 14 mg
GLP1SemaglutideSEMAGCARELaos; Food and Drug DepartmentOrally once dailyBoten Elemento Pharmaceutical2024Tablets: 14 mg
GLP1SemaglutideSEMAGLUTIDE (Tongmeng Lao)Laos; Food and Drug DepartmentOrally once dailyTongmeng Lao Pharmaceutical2024Tablets: 7; 14 mg
GLP1SemaglutideSEMAGLUTIDE (Factory No. 3)Laos; Food and Drug DepartmentOrally once dailyPharmaceutical Factory No. 32025Tablets: 7; 14 mg
GLP1LiraglutideVictozaUnited States, EU, and multiple marketsSubcutaneous injection once dailyNovo Nordisk2009/20100.6; 1.2; 1.8 mg
GLP1LiraglutideSaxendaUnited States, EU, and multiple marketsSubcutaneous injection once dailyNovo Nordisk2014/20150.6; 1.2; 1.8; 2.4; 3 mg
GLP1LiraglutideLiraglutide Injection (gVictoza)United States; FDASubcutaneous injection once dailyHikma Pharmaceuticals20240.6; 1.2; 1.8 mg
GLP1LiraglutideLiraglutide Injection (authorized generic Victoza)United States; FDASubcutaneous injection once dailyTeva Pharmaceuticals USA20240.6; 1.2; 1.8 mg
GLP1LiraglutideLiraglutide Injection (gSaxenda)United States; FDASubcutaneous injection once dailyTeva Pharmaceuticals USA20250.6; 1.2; 1.8; 2.4; 3 mg
GLP1LiraglutideLiraglutide Injection (gVictoza)United States; FDASubcutaneous injection once dailyBiocon20260.6; 1.2; 1.8 mg
GLP1LiraglutideLiraglutide Injection (gSaxenda)United States; FDASubcutaneous injection once dailyBiocon20260.6; 1.2; 1.8; 2.4; 3 mg
GLP1LiraglutideLiraglutide Injection (gSaxenda)United States; FDASubcutaneous injection once dailyCipla / Orbicular20260.6; 1.2; 1.8; 2.4; 3 mg
GLP1LiraglutideBiolideUnited Kingdom; MHRASubcutaneous injection once dailyBiocon Pharma UK20250.6; 1.2; 1.8; 2.4; 3 mg
GLP1LiraglutideLiraglutide BioconUnited Kingdom; MHRASubcutaneous injection once dailyBiocon Pharma UK20250.6; 1.2; 1.8 mg
GLP1LiraglutideDiavicUnited Kingdom; MHRASubcutaneous injection once dailyRanbaxy UK / Sun Pharma≤20260.6; 1.2; 1.8 mg
GLP1LiraglutideNevolatUnited Kingdom; MHRASubcutaneous injection once dailyZentiva20260.6; 1.2; 1.8; 2.4; 3 mg
GLP1LiraglutidePlaobesUnited Kingdom; MHRASubcutaneous injection once dailyCipla EU Ltd20260.6; 1.2; 1.8; 2.4; 3 mg
GLP1LiraglutideZegluxenUnited Kingdom; MHRASubcutaneous injection once dailyZentiva20260.6; 1.2; 1.8 mg
GLP1LiraglutideLiraglutide Dr. Reddy’sUnited Kingdom; MHRASubcutaneous injection once dailyDr. Reddy’s Laboratories20260.6; 1.2; 1.8 mg
GLP1LiraglutideAblymicoEuropean Union; EMA/European CommissionSubcutaneous injection once dailySTADA Arzneimittel AG20260.6; 1.2; 1.8; 2.4; 3 mg
GLP1LiraglutideLiraglutide STADAEuropean Union; EMA/European CommissionSubcutaneous injection once dailySTADA Arzneimittel AG20260.6; 1.2; 1.8 mg
GLP1LiraglutideDiavorinNetherlands; national marketing authorizationSubcutaneous injection once dailyBiocon; distributed by Pharmamedic B.V.20250.6; 1.2; 1.8 mg
GLP1LiraglutideVobexorynNetherlands; national marketing authorizationSubcutaneous injection once dailyBiocon; distributed by Pharmamedic B.V.20250.6; 1.2; 1.8; 2.4; 3 mg
GLP1LiraglutideBenedoAustralia; TGASubcutaneous injection once dailySun Pharma ANZ20250.6; 1.2; 1.8; 2.4; 3 mg
GLP1LiraglutideLiraglutide RBXAustralia; TGASubcutaneous injection once dailySun Pharma ANZ20250.6; 1.2; 1.8; 2.4; 3 mg
GLP1LiraglutideLiraglutide SUNAustralia; TGASubcutaneous injection once dailySun Pharma ANZ20250.6; 1.2; 1.8; 2.4; 3 mg
GLP1LiraglutideLilupingChina; NMPASubcutaneous injection once dailyHuadong Medicine / Hangzhou Zhongmei Huadong20230.6; 1.2; 1.8 mg; titration up to 3 mg for obesity
GLP1LiraglutideTongboliChina; NMPASubcutaneous injection once dailyTonghua Dongbao20230.6; 1.2; 1.8 mg
GLP1LiraglutideBeilelinChina; NMPASubcutaneous injection once dailyChia Tai Tianqing / Sino Biopharm20240.6; 1.2; 1.8 mg
GLP1LiraglutideLirafitIndia; DCGI/CDSCOSubcutaneous injection once dailyGlenmark Pharmaceuticals20240.6; 1.2; 1.8 mg
GLP1LiraglutideLiraglutide InjectionIndia; DCGI/CDSCOSubcutaneous injection once dailyBiocon Pharma20250.6; 1.2; 1.8 mg
GLP1LiraglutideMelitideIran; IFDA; also the Russian FederationSubcutaneous injection once dailyCinnaGen≤20240.6; 1.2; 1.8 mg
GLP1LiraglutideMasizaIran; IFDA; also the Russian FederationSubcutaneous injection once dailyCinnaGen≤20250.6; 1.2; 1.8; 2.4; 3 mg
GLP1LiraglutideVesfolRussian Federation; active marketing authorizationSubcutaneous injection once dailyRus Biopharm / PSK Pharma20230.6; 1.2; 1.8 mg
GLP1LiraglutideKvinliroRussian Federation; active marketing authorizationSubcutaneous injection once dailyBiokhimik / Medsintez20230.6; 1.2; 1.8 mg
GLP1LiraglutideMasizaRussian Federation; active marketing authorizationSubcutaneous injection once dailySNS / CinnaGen20250.6; 1.2; 1.8; 2.4; 3 mg
GLP1LiraglutideMelitideRussian Federation; active marketing authorizationSubcutaneous injection once dailySNS / CinnaGen20240.6; 1.2; 1.8 mg
GLP1LiraglutideShugalesRussian Federation; active marketing authorizationSubcutaneous injection once dailyPSK Pharma20230.6; 1.2; 1.8; 2.4; 3 mg
GLP1LiraglutideEnligriyaRussian Federation; active marketing authorizationSubcutaneous injection once dailyPROMOMED RUS / Biokhimik / Medsintez20230.6; 1.2; 1.8; 2.4; 3 mg
GLP1+GIPTirzepatideMounjaroUnited States, EU, United Kingdom, Canada, China, India, and many other marketsSubcutaneous injection once weeklyEli Lilly20222.5; 5; 7.5; 10; 12.5; 15 mg
GLP1+GIPTirzepatideZepboundUnited States and selected marketsSubcutaneous injection once weeklyEli Lilly20232.5; 5; 7.5; 10; 12.5; 15 mg
GLP1+GIPTirzepatideYurpeakIndia; DCGI/CDSCOSubcutaneous injection once weeklyEli Lilly; commercial partner Cipla20252.5; 5; 7.5; 10; 12.5; 15 mg
GLP1+GIPTirzepatideSejaroRussian Federation; active marketing authorizationSubcutaneous injection once weeklyGEROPHARM20252.5; 5; 7.5; 10; 12.5; 15 mg
GLP1+GIPTirzepatideTirzettaRussian Federation; active marketing authorizationSubcutaneous injection once weeklyPROMOMED RUS / Biokhimik / Medsintez20252.5; 5; 7.5; 10; 12.5; 15 mg
GLP1+GIPTirzepatideTirzero SlimRussian Federation; active marketing authorizationSubcutaneous injection once weeklyPSK Pharma20262.5; 5; 7.5; 10; 12.5; 15 mg
GLP1+GIPTirzepatideTirlideyaRussian Federation; active marketing authorizationSubcutaneous injection once weeklyPharmasyntez-Nord20262.5; 5; 7.5; 10; 12.5; 15 mg
GLP1+GIPTirzepatideSpartinaIran; IFDASubcutaneous injection once weeklyCinnaGen / Orchid Pharmed20252.5; 5; 7.5; 10; 12.5; 15 mg
GLP1+GIPTirzepatideDuotirBangladesh; legally marketed nationallySubcutaneous injection once weeklyOpsonin Pharma Ltd.≤2026; exact date of first launch not publicly established2.5; 5; 7.5 mg
GLP1+GIPTirzepatideMontaroBangladesh; legally marketed nationallySubcutaneous injection once weeklySquare Pharmaceuticals PLC≤2026; exact date of first launch not publicly established2.5; 5 mg
GLP1+GIPTirzepatideMounviaBangladesh; legally marketed nationallySubcutaneous injection once weeklySynovia Pharma PLC≤2026; exact date of first launch not publicly established2.5; 5 mg
GLP1+GIPTirzepatideTirzaBangladesh; legally marketed nationallySubcutaneous injection once weeklyBeacon Pharmaceuticals PLC≤2026; exact date of first launch not publicly established2.5; 5; 7.5 mg
GLP1+GIPTirzepatideTirzemaBangladesh; legally marketed nationallySubcutaneous injection once weeklyIncepta Pharmaceuticals Ltd.≤2026; exact date of first launch not publicly established2.5; 5; 7.5 mg
GLP1+GIPTirzepatideTirzepBangladesh; legally marketed nationallySubcutaneous injection once weeklyACI Limited≤2026; exact date of first launch not publicly established2.5; 5; 7.5; 10; 12.5; 15 mg
GLP1+GIPTirzepatideTizaroBangladesh; legally marketed nationallySubcutaneous injection once weeklyZiska Pharmaceuticals Ltd.≤2026; exact date of first launch not publicly established2.5; 5; 7.5 mg
GLP1+GIPTirzepatideTyzepaBangladesh; legally marketed nationallySubcutaneous injection once weeklyDrug International Ltd.≤2026; exact date of first launch not publicly established2.5; 5; 7.5 mg
GLP1+GIPTirzepatideWikijetBangladesh; legally marketed nationallySubcutaneous injection once weeklyAristopharma Ltd.≤2026; exact date of first launch not publicly established2.5; 5; 7.5 mg
GLP1+GIPTirzepatideZepatidBangladesh; legally marketed nationallySubcutaneous injection once weeklyPopular Pharmaceuticals Ltd.≤2026; exact date of first launch not publicly established2.5; 5; 7.5 mg
GLP1+GIPTirzepatideZepterBangladesh; legally marketed nationallySubcutaneous injection once weeklyEskayef Pharmaceuticals Ltd.≤2026; exact date of first launch not publicly established2.5; 5; 7.5 mg
GLP1+GIPTirzepatideZeptideBangladesh; legally marketed nationallySubcutaneous injection once weeklyBeximco Pharmaceuticals Ltd.≤2026; exact date of first launch not publicly established2.5; 5; 7.5 mg